Kajosaari, Lauri I <br/><br/>
Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide.  [electronic resource] 

 -  European journal of clinical pharmacology  Mar 2006 
 - 217-23 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0031-6970 
<br/><br/><label>Standard No.: </label>10.1007/s00228-005-0093-8  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Area Under Curve<br/>Aryl Hydrocarbon Hydroxylases--antagonists & inhibitors<br/>Blood Glucose--metabolism<br/>Capsules<br/>Carbamates--blood<br/>Chromatography, Liquid--methods<br/>Cross-Over Studies<br/>Cytochrome P-450 CYP2C8<br/>Cytochrome P-450 CYP3A<br/>Cytochrome P-450 Enzyme Inhibitors<br/>Cytochrome P-450 Enzyme System--metabolism<br/>Drug Administration Schedule<br/>Enzyme Inhibitors--blood<br/>Female<br/>Gas Chromatography-Mass Spectrometry--methods<br/>Half-Life<br/>Humans<br/>Hypoglycemic Agents--administration & dosage<br/>In Vitro Techniques<br/>Male<br/>Pioglitazone<br/>Piperidines--blood<br/>Substrate Specificity<br/>Thiazolidinediones--administration & dosage